Show simple item record

dc.contributor.authorGeorgopoulou, D
dc.contributor.authorCallari, M
dc.contributor.authorRueda, OM
dc.contributor.authorShea, A
dc.contributor.authorMartin, A
dc.contributor.authorGiovannetti, A
dc.contributor.authorQosaj, F
dc.contributor.authorDariush, A
dc.contributor.authorChin, S-F
dc.contributor.authorCarnevalli, LS
dc.contributor.authorProvenzano, E
dc.contributor.authorGreenwood, W
dc.contributor.authorLerda, G
dc.contributor.authorEsmaeilishirazifard, E
dc.contributor.authorO'Reilly, M
dc.contributor.authorSerra, V
dc.contributor.authorBressan, D
dc.contributor.authorIMAXT Consortium
dc.contributor.authorMills, GB
dc.contributor.authorAli, HR
dc.contributor.authorCosulich, SS
dc.contributor.authorHannon, GJ
dc.contributor.authorBruna, A
dc.contributor.authorCaldas, C
dc.date.accessioned2021-06-11T11:38:15Z
dc.date.available2021-06-11T11:38:15Z
dc.date.issued2021-03-31
dc.identifier.citationNature communications, 2021, 12 (1), pp. 1998 - ?
dc.identifier.issn2041-1723
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4619
dc.identifier.eissn2041-1723
dc.identifier.doi10.1038/s41467-021-22303-z
dc.description.abstractThe heterogeneity of breast cancer plays a major role in drug response and resistance and has been extensively characterized at the genomic level. Here, a single-cell breast cancer mass cytometry (BCMC) panel is optimized to identify cell phenotypes and their oncogenic signalling states in a biobank of patient-derived tumour xenograft (PDTX) models representing the diversity of human breast cancer. The BCMC panel identifies 13 cellular phenotypes (11 human and 2 murine), associated with both breast cancer subtypes and specific genomic features. Pre-treatment cellular phenotypic composition is a determinant of response to anticancer therapies. Single-cell profiling also reveals drug-induced cellular phenotypic dynamics, unravelling previously unnoticed intra-tumour response diversity. The comprehensive view of the landscapes of cellular phenotypic heterogeneity in PDTXs uncovered by the BCMC panel, which is mirrored in primary human tumours, has profound implications for understanding and predicting therapy response and resistance.
dc.formatElectronic
dc.format.extent1998 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectIMAXT Consortium
dc.subjectCell Line, Tumor
dc.subjectAnimals
dc.subjectMice, Inbred NOD
dc.subjectMice, Knockout
dc.subjectHumans
dc.subjectMice, SCID
dc.subjectBreast Neoplasms
dc.subjectBenzamides
dc.subjectMorpholines
dc.subjectPiperazines
dc.subjectPyridines
dc.subjectPyrimidines
dc.subjectProtein Kinase Inhibitors
dc.subjectTreatment Outcome
dc.subjectXenograft Model Antitumor Assays
dc.subjectDrug Resistance, Neoplasm
dc.subjectFemale
dc.subjectMCF-7 Cells
dc.subjectHeterografts
dc.titleLandscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response.
dc.typeJournal Article
dcterms.dateAccepted2021-02-26
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41467-021-22303-z
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-03-31
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNature communications
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Preclinical Modelling of Paediatric Cancer Evolution
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Preclinical Modelling of Paediatric Cancer Evolution
pubs.publication-statusPublished
pubs.volume12
pubs.embargo.termsNot known
icr.researchteamPreclinical Modelling of Paediatric Cancer Evolution
icr.researchteamPreclinical Modelling of Paediatric Cancer Evolutionen_US
dc.contributor.icrauthorBruna Cabot, Alejandraen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0